Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study
Authors' conclusion
Oral semaglutide demonstrated higher clinical effectiveness and strong economic favorability relative to dulaglutide, supporting its potential inclusion in Taiwan NHI formulary to optimize the allocation of healthcare resources in T2DM.
Study context
- Population
- Patients with T2D, Taiwan (simulated cohort)
- Comparison
- Oral semaglutide vs subcutaneous dulaglutide
- Outcome
- Cost-effectiveness (incremental QALYs, costs and cost-utility ratio); WTP threshold US$33,983
- Follow-up
- 10-year horizon
Methodological detailsMarkov model study, Markov decision-analytic model, 10-year horizon, Taiwanese healthcare payer perspective, 3% annual discounting, probabilistic and one-way sensitivity analyses
- Markov model study
- Markov decision-analytic model
- 10-year horizon
- Taiwanese healthcare payer perspective
- 3% annual discounting
- Probabilistic and one-way sensitivity analyses
Main finding
As reported in the abstract
Cost-effectiveness · 10 years
Incremental quality-adjusted life years (QALYs)
0.33 QALYs
Cost-effectiveness
Cost reduction
1,137 US$
lower costs with oral semaglutide
Incremental cost-utility ratio
−3,478.66 US$/QALYs
Cost-effectiveness
Further findings
Sensitivity analyses
- Probability of cost-effectiveness across all willingness-to-pay (WTP) thresholds
- 96.5%
- Cost differences most sensitive to drug price, particularly in patients without CVD
Original publication
Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study. Diabetes Res Clin Pract. Published 23 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →